GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Intrinsic Value: Projected FCF

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Intrinsic Value: Projected FCF : $-0.19 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-28), Innovation Pharmaceuticals's Intrinsic Value: Projected FCF is $-0.19. The stock price of Innovation Pharmaceuticals is $0.003. Therefore, Innovation Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Innovation Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:

IPIX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.28
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Innovation Pharmaceuticals Intrinsic Value: Projected FCF Historical Data

The historical data trend for Innovation Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Intrinsic Value: Projected FCF Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 -0.43 -0.28 -0.19 -0.21

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.23 -0.23 -0.21 -0.19

Competitive Comparison of Innovation Pharmaceuticals's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Innovation Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Price-to-Projected-FCF falls into.



Innovation Pharmaceuticals Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Innovation Pharmaceuticals's Free Cash Flow(6 year avg) = $-6.85.

Innovation Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep23)*0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*-6.85312+1.162*0.8)/518.348
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation Pharmaceuticals  (OTCPK:IPIX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Innovation Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.003/-0.19470692788453
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation Pharmaceuticals Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus